EGFR blockade with ZD1839 (IRESSA) potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 squamous cell carcinomaSOLOMON, Benjamin; HAGEKYRIAKOU, Jim; TRIVETT, Melanie K et al.International journal of radiation oncology, biology, physics. 2003, Vol 55, Num 3, pp 713-723, issn 0360-3016, 11 p.Article

Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitorsBIANCO, Roberto; INCHEOL SHIN; RITTER, Christoph A et al.Oncogene (Basingstoke). 2003, Vol 22, Num 18, pp 2812-2822, issn 0950-9232, 11 p.Article

Characterization of sequence-dependent synergy between ZD1839 ('Iressa') and oxaliplatinXU, Jian-Ming; AZZARITI, Amalia; SEVERINO, Montemuro et al.Biochemical pharmacology. 2003, Vol 66, Num 4, pp 551-563, issn 0006-2952, 13 p.Article

Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumorsCHUNHUA LU; SPEERS, Corey; MOHSIN, Syed K et al.Journal of the National Cancer Institute. 2003, Vol 95, Num 24, pp 1825-1833, issn 0027-8874, 9 p.Article

Phase I studies of ZD1839 in patients with common solid tumorsLORUSSO, Patricia M.Seminars in oncology. 2003, Vol 30, Num 1, pp 21-29, issn 0093-7754, 9 p., SUP1Article

Dose-comparative monotherapy trials of ZD1839 in previously treated non-small cell lung cancer patientsHERBST, Roy S.Seminars in oncology. 2003, Vol 30, Num 1, pp 30-38, issn 0093-7754, 9 p., SUP1Article

Development of ZD 1839 in colorectal cancerDOUGLASS, Edwin C.Seminars in oncology. 2003, Vol 30, Num 3, pp 17-22, issn 0093-7754, 6 p., SUP6Article

ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: Results of a phase I trialRANSON, Malcolm; HAMMOND, Lisa A; FEYEREISLOVA, Andrea et al.Journal of clinical oncology. 2002, Vol 20, Num 9, pp 2240-2250, issn 0732-183XArticle

New therapeutic agents targeting the epidermal growth factor receptorBASELGA, José.Journal of clinical oncology. 2000, Vol 18, Num 21, pp 54s-59s, issn 0732-183X, SUPArticle

Results of the Southwest Oncology Group phase II evaluation (study SOO31) of ZD1839 for advanced transitional cell carcinoma of the urotheliumPETRYLAK, Daniel P; TANGEN, Catherine M; VAN VELDHUIZEN, Peter J et al.BJU international (Papier). 2010, Vol 105, Num 3, pp 317-321, issn 1464-4096, 5 p.Article

The effects of ZD1839 (Iressa), a highly selective EGFR tyrosine kinase inhibitor, as a radiosensitiser in bile duct carcinoma cell linesMIYATA, Hideki; SASAKI, Tamito; KUWAHARA, Kenichi et al.International journal of oncology. 2006, Vol 28, Num 4, pp 915-921, issn 1019-6439, 7 p.Article

Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neckCOHEN, Ezra E. W; ROSEN, Fred; STADLER, Walter M et al.Journal of clinical oncology. 2003, Vol 21, Num 10, pp 1980-1987, issn 0732-183X, 8 p.Article

The sensitivity of lung cancer cell lines to the EGFR-selective tyrosine kinase inhibitor ZD1839 ('Iressa'¹) is not related to the expression of EGFR or HER-2 or to K-ras gene statusSUZUKI, Takeshi; NAKAGAWA, Taku; ENDO, Hideki et al.Lung cancer. 2003, Vol 42, Num 1, pp 35-41, issn 0169-5002, 7 p.Article

Impact of ZD1839 on non-small cell lung cancer-related symptoms as measured by the functional assessment of cancer therapy-lung scaleCELLA, David.Seminars in oncology. 2003, Vol 30, Num 1, pp 39-48, issn 0093-7754, 10 p., SUP1Article

Ocular findings in patients with solid tumours treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('iressa', ZD1839) in phase I and II clinical trialsTULLO, A. B; ESMAELI, B; MURRAY, P. I et al.Eye (London. 1987). 2005, Vol 19, Num 7, pp 729-738, issn 0950-222X, 10 p.Article

Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumorsNAKAGAWA, K; TAMURA, T; FUKUOKA, M et al.Annals of oncology. 2003, Vol 14, Num 6, pp 922-930, issn 0923-7534, 9 p.Article

Time and dose-dependent radiosensitization of the glioblastoma multiforme U251 cells by the EGFf receptor tyrosine kinase inhibitor ZD1839 ('Iressa')STEA, Baldassarre; FALSEY, Ryan; KISLIN, Kerri et al.Cancer letters. 2003, Vol 202, Num 1, pp 43-51, issn 0304-3835, 9 p.Article

Studies with ZD1839 in preclinical modelsSIROTNAK, Francis M.Seminars in oncology. 2003, Vol 30, Num 1, pp 12-20, issn 0093-7754, 9 p., SUP1Article

Antitumor activity of the selective epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) Iressa® (ZD1839) in an EGFR-expressing multidrug-resistant cell line in vitro and in vivoNARUSE, Ichiro; OHMORI, Tohru; AO, Yoko et al.International journal of cancer. 2002, Vol 98, Num 2, pp 310-315, issn 0020-7136Article

ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancerRABEN, David; HELFRICH, Barbara A; CHAN, Dan et al.Seminars in oncology. 2002, Vol 29, Num 1, pp 37-46, issn 0093-7754, SUP4Article

New cytotoxicsCRINO, L.Lung cancer. 2002, Vol 38, Num 1, pp S41-S42, issn 0169-5002Conference Paper

Ciblage du récepteur aux facteurs de croissance épithéliaux (REGF) par les inhibiteurs de tyrosine kinase et applications dans les cancers colorectaux = Targeting epidermal growth factor receptor (EGFR) by inhibitors of tyrosine kinase: practical approach regarding colorectal cancerMAGNE, N; TOILLON, R.-A.Oncologie (Paris). 2004, Vol 6, Num 1, pp 41-45, issn 1292-3818, 5 p.Article

Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinomaHÖPFNER, Michael; SUTTER, Andreas P; HUETHER, Alexander et al.Journal of hepatology. 2004, Vol 41, Num 6, pp 1008-1016, issn 0168-8278, 9 p.Article

Developing inhibitors of the epidermal growth factor receptor for cancer treatmentGRÜNWALD, Viktor; HIDALGO, Manuel.Journal of the National Cancer Institute. 2003, Vol 95, Num 12, pp 851-867, issn 0027-8874, 17 p.Article

Targeting epidermal growth factor receptor-tyrosine kinase in the most common solid tumorsBUNN, Paul A.Seminars in oncology. 2003, Vol 30, Num 1, issn 0093-7754, 56 p., SUP1Serial Issue